Clinical Trial Update: Berinert P Study of Subcutaneous Versus Intravenous Administration [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing subcutaneous versus intravenous administration of Berinert P for hereditary angioedema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Berinert P (C1 esterase inhibitor, human)

Snippet

Sponsor: Johann Wolfgang Goethe University Hospital | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED